Third-generation CAR T cell therapy targeting relapsed or refractory CD19+lymphoid disease (HD-CAR-1)

被引：0
|
作者：
Schubert, M. -L. [1 ]
Schmitt, A. [1 ]
Neuber, B. [1 ]
Hueckelhoven-Krauss, A. [1 ]
Kunz, A. [1 ]
Wang, L. [1 ]
Gern, U. [1 ]
Michels, B. [1 ]
Sellner, L. [1 ]
Hofmann, S. [1 ]
Mueller-Tidow, C. [1 ]
Dreger, P. [1 ]
Schmitt, M. [1 ]
机构：
[1] Univ Klinikum Heidelberg, Med Klin 5, Heidelberg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V840
引用
收藏
页码：236 / 236
页数：1
相关论文
共 50 条
  • [41] Phenotypic Analysis of Baseline T cell Subsets and Third Generation CD20 Targeted CAR T cell Products for Treatment of Relapsed/Refractory Follicular Lymphoma
    Mo, George
    Lee, Sang Yun
    Voutsinas, Jenna M.
    Wu, Qian
    Lee, Dong Hoon
    Gauthier, Jordan
    Hirayama, Alexandre V.
    Maloney, David G.
    Shadman, Mazyar
    Till, Brian G.
    BLOOD, 2023, 142
  • [42] 3rd-generation CD19-directed chimeric antigen receptor t-cells (carts) for relapsed/refractory chronic lymphocytic leukemia (cll) - results from an academic phase 1/2 trial (hd-car-1)
    Derigs, P.
    Kunz, A.
    Dreger, P.
    Schmitt, A.
    Schubert, M. -L.
    Brueggemann, M.
    Bernhard, H.
    Kobbe, G.
    Lindemann, A.
    Rummel, M.
    Wang, L.
    Michels, B.
    Waldhoff, P.
    Korell, F.
    Pavel, P.
    Ho, A. D.
    Muller-Tidow, C.
    Schmitt, M.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 129 - 130
  • [43] Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)
    Yang, Ping
    Liu, Shuozi
    Zhang, Weilong
    Wang, Jing
    Jing, Hongmei
    BLOOD, 2023, 142
  • [44] Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
    Yang, Tingting
    Dong, Yetian
    Zhang, Mingming
    Feng, Jingjing
    Fu, Shan
    Xiao, Pingnan
    Hong, Ruimin
    Xu, Huijun
    Cui, Jiazhen
    Huang, Simao
    Wei, Guoqing
    Chang, Alex H.
    Huang, He
    Hu, Yongxian
    BLOOD, 2024, 144 : 2819 - 2819
  • [45] Third Generation CD19-CAR T Cells for Relapsed and Refractory Lymphoma and Leukemia Report from the Swedish Phase I/IIa Trial
    Enblad, Gunilla
    Karlsson, Hannah
    Wikstrom, Kristina
    Essand, Magnus
    Savoldo, Barbara
    Brenner, Malcolm K.
    Dotti, Gianpietro
    Hallbook, Helene
    Hoglund, Martin
    Hagberg, Hans
    Loskog, Angelica
    BLOOD, 2015, 126 (23)
  • [46] Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
    Fredon, Maxime
    Poussard, Margaux
    Biichle, Sabeha
    Bonnefoy, Francis
    Mantion, Charles-Frederic
    Seffar, Evan
    Renosi, Florian
    Bole-Richard, Elodie
    Boidot, Romain
    Chevrier, Sandrine
    Anna, Francois
    Loustau, Maria
    Caumartin, Julien
    Goncalves-Venturelli, Mathieu
    Robinet, Eric
    Saas, Philippe
    Deconinck, Eric
    Daguidau, Etienne
    Roussel, Xavier
    Godet, Yann
    Adotevi, Olivier
    Angelot-Delettre, Fanny
    Galaine, Jeanne
    Garnache-Ottou, Francine
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (08) : 1090 - 1107
  • [47] Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
    Su, Yi-Jiun
    Kramer, Anne Marijn
    Hamilton, Mark P.
    Agarwal, Neha
    Srinagesh, Hrishikesh K.
    Baird, John H.
    Sahaf, Bita
    Kuo, Adam
    Ehlinger, Zachary J.
    Desai, Moksha H.
    Rietberg, Skyler P.
    Tunuguntla, Ramya
    Patel, Shabnum
    Chinnasamy, Harshini
    Gkitsas-Long, Nikolaos
    Klysz, Dorota D.
    Brown, Annie Kathleen
    Bharadwaj, Sushma
    Dahiya, Saurabh
    Smith, Melody
    Muffly, Lori
    Mackall, Crystal L.
    Good, Zinaida
    Feldman, Steven A.
    Miklos, David B.
    Frank, Matthew J.
    CANCER DISCOVERY, 2025, 15 (04) : 733 - 747
  • [48] Efficacy and side effects of anti-CD19 CAR T-cell therapy in patients with relapsed/refractory gastrointestinal lymphoma
    Jiang, Yi Li
    Mu, Juan
    Cui, Rui
    Li, Xin
    Wang, Jia
    Li, Qing
    Li, Jingyi
    Mou, Nan
    Deng, Qi
    CANCER MEDICINE, 2024, 13 (04):
  • [49] CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
    Katherine C. Pehlivan
    Brynn B. Duncan
    Daniel W. Lee
    Current Hematologic Malignancy Reports, 2018, 13 : 396 - 406
  • [50] CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
    Pehlivan, Katherine C.
    Duncan, Brynn B.
    Lee, Daniel W.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (05) : 396 - 406
12345